JOURNAL OF SHANDONG UNIVERSITY (OTOLARYNGOLOGY AND OPHTHALMOLOGY) ›› 2016, Vol. 30 ›› Issue (4): 101-104.doi: 10.6040/j.issn.1673-3770.0.2015.481

Previous Articles     Next Articles

Changes of ocular hemodynamics after intravitreal ranibizumab injection in patients with wet age-related macular degeneration.

ZHAO Lu, XIE Guoli, WANG Yanling   

  1. Department of Ophthalmology, Beijing Friendship Hospital, Capital Medical University, Beijing 100050, China
  • Received:2015-11-12 Online:2016-08-16 Published:2016-08-16

PDF (PC)

780

Abstract: Objective To evaluate the changes in retrobulbar blood flow by using color Doppler sonography in patients who had undergone a single intravitreal ranibizumab injection for wet age-related macular degeneration(wAMD). Methods 20 wAMD patients(20 eyes)who had undergone intravitreal 0.5 mg ranibizumab injection were enrolled in this study. The ophthalmic artery, central retinal artery and ciliary artery of both eyes of patients were evaluated by color Doppler sonography. Peak systolic velocity(PSV), end-diastolic velocity(EDV), and resistance index(RI)and pulsatility index(PI)values were calculated before injection, and after injection on day 7 and day 30. The differences of ocular hemodynamic parameters were analysed at different time points. Results In a comparison with the pre-injection values of PSV, EDV, RI and PI, the post-injection values at both 1 and 4 week showed no statistically significant difference in ophthalmic artery, central retinal artery and lateral posterior ciliary artery. Similarly, all the same parameters revealed no statistically significant difference in the un-injected healthy fellow eyes. Conclusion Intravitreal ranibizumab injection for wAMD does not cause a significant difference in the retrobulbar blood flow in either the injected eye or the fellow eye.

Key words: Ranibizumab, Retrobulbar blood flow, Wet age-related macular degeneration

CLC Number: 

  • R774.5
[1] Furino C, Boscia F, Cardascia N, et al. Hemorrhagic macular infarction after intravitreal bevacizumab for central retinal vein occlusion[J]. Ophthalmic Surg Lasers Imaging, 2010, 9(1):1-2.
[2] Ganssauge M, Wilhelm H, Bartz-Schmidt K U, et al. Non-arteritic anterior ischemic optic neuropathy(NA-AION)after intravitreal injection of bevacizumab(Avastin_)for treatment of angoid streaks in pseudoxanthoma elasticum[J]. GraefesArch Clin Exp Ophthalmol, 2009, 247(12):1707-1710.
[3] Huang Z L, Lin K H, Lee Y C, et al. Acute vision loss after intravitreal injection of bevacizumab(avastin)associated with ocular ischemic syndrome[J]. Ophthalmologica, 2010, 224(2):86-89.
[4] Mansour A M, Bynoe L A, Welch J C, et al. Retinal vascular events after intravitreal bevacizumab[J]. Acta Ophthalmol, 2010, 88(7):730-735.
[5] Schmidt-Erfurth U. Clinical safety of ranibizumab in age-reIated macular degeneration[J]. Expert Opin Drug Saf, 2010, 9(1):149-165.
[6] Dimitrova G, Tamaki Y, Kato S. Retrobulbar circulation in patients with age-related maculopathy[J]. Eye, 2002, 16(5):580-586.
[7] Dimitrova G, Kato S. Color Doppler imaging of retinal diseases[J]. Surv Ophthalmol, 2010, 55(3):193-214.
[8] Friedman E, Krupsky S, Lane A M, et al. Ocular blood flow velocity in age-related macular degeneration[J]. Ophthalmology, 1995, 102(4):640.
[9] 李惠荣,李惠玲,吴秀荣,等.彩色多普勒超声对年龄相关性黄斑变性患者眼血流动力学的评价[J].山东医药, 2009, 49(41):84-85.
[10] Hosseini H, Lotfi M, Esfahani M H, et al.Effect of intravitreal bevacizumab on retrobulbar blood flow in njected and uninjected fellow eyes of patients with neovascular age-related macular degeneration[J]. Retina, 2012, 32(5):967-971.
[11] Toklu Y, Cakmak H B, Raza S, et al. Short-term effects of intravitreal bevacizumab(Avastin(®))on retrobulbar hemodynamics in patients with neovascular age-related macular degeneration[J]. Acta Ophthalmol, 2011, 89(1):e41-45.
[12] Yuksel K, Altinkaynak H, Kina A, et al. Can intravitreal ranibizumab alter retrobulbar circulation in eye with age- related macular degeneration?[J]. J Ocul Pharmacol Ther, 2013, 29(8):723-727.
[13] Sakalar Y B, Senturk S, Yildirim M, et al. Evaluation of retrobulbar blood flow by color doppler ultrasonography after intravitreal ranibizumab injection in patients with neovascular age-related macular degeneration[J]. J Clin Ultrasound, 2013, 41(1):32-37.
[14] Zhu Q, Ziemssen F, Henke-Fahle S, et al. Vitreous levels of bevacizumab and vascular endothelial growth factor-A in patients with choroidal neovascularization[J]. Ophthalmology, 2008, 115(10):1750-1755.
[1] SUN Qingzhu, SHEN Jian, CHEN Xing, WU Yanbing, ZENG Lun. The role of metabolic indicators in predicting ranibizumab efficacy in diabetic macular edema [J]. Journal of Otolaryngology and Ophthalmology of Shandong University, 2026, 40(1): 74-81.
[2] WANG Luping, KOU Fangning, WANG Hao, ZHANG Canwei, WANG Yanling, YOU Ran, WU Weizhen. Effects of subretinal hyperreflective material on the visual prognosis of anti-VEGF therapy in patients with neovascular macular degeneration [J]. Journal of Otolaryngology and Ophthalmology of Shandong University, 2022, 36(6): 101-105.
[3] GU Ranran, LI Fengjiao, JIAO Wanzhen, CUI Yanyan, ZHAO Bojun. Clinical efficacy of lecithin complex iodine capsule in the adjuvant treatment of retinal vein occlusion [J]. Journal of Otolaryngology and Ophthalmology of Shandong University, 2022, 36(5): 46-50.
[4] ZHANG Taoran, WANG Wei, LI Mingming, HUANG Yingxiang. Subfoveal choroidal thickness changes following intravitreal ranibizumab treatment in choroidal neovascularization due to pathological myopia [J]. Journal of Otolaryngology and Ophthalmology of Shandong University, 2022, 36(2): 68-71.
[5] ZHOU Xueyi, LI Yiming, WANG Meiju, ZHANG Yuanyuan, ZHANG Lizhuo. The application of 25-gauge minimally invasive vitreoretinal surgery combined with intravitreal ranibizumab injections in the treatment of proliferative diabetic retinopathy. [J]. JOURNAL OF SHANDONG UNIVERSITY (OTOLARYNGOLOGY AND OPHTHALMOLOGY), 2017, 31(4): 87-89.
[6] WANG Cui, YAN Xin, ZHAO Bojun. Combination of intravitreal ranibizumab with photodynamic therapy in the treatment of wet age-related macular degeneration. [J]. JOURNAL OF SHANDONG UNIVERSITY (OTOLARYNGOLOGY AND OPHTHALMOLOGY), 2017, 31(4): 94-97.
[7] . Clinical observation on the treatment of CSME and NCSME by intravitreal injection of ranibizumab. [J]. JOURNAL OF SHANDONG UNIVERSITY (OTOLARYNGOLOGY AND OPHTHALMOLOGY), 2017, 31(2): 96-98.
[8] . Clinical observation on the treatment of BRVO-ME by the combination of laser therapy with Ranibizumab intravitreal injection. [J]. JOURNAL OF SHANDONG UNIVERSITY (OTOLARYNGOLOGY AND OPHTHALMOLOGY), 2017, 31(1): 110-113.
[9] CHAI Xuerong, ZHANG Shixi, TAO Yu, SHEN Jiaquan. Effect of intravitreal ranibizumab injection combined with trabelectomy and panretinal photocoagulation for neovascular glaucoma [J]. JOURNAL OF SHANDONG UNIVERSITY (OTOLARYNGOLOGY AND OPHTHALMOLOGY), 2015, 29(3): 72-75.
[10] ZI Yu-meng1, WANG Yu2, FAN Chuan-feng2, SHU Xiang-wen2, WU Chang-long2. Intravitreal injection of Ranibizumab for idiopathic choroidal neovascularization lesion in two courses [J]. JOURNAL OF SHANDONG UNIVERSITY (OTOLARYNGOLOGY AND OPHTHALMOLOGY), 2014, 28(3): 63-66.
Viewed
Full text


Abstract

Cited
  Shared   
  Discussed   
No Suggested Reading articles found!
Website Copyright: Editorial Office of Journal of Otolaryngology and Ophthalmology of Shandong University
Address: No.27 Shanda South Road, Jinan, Shandong, China. Post code: 250100 Tel: +86-0531-88366912 Email: ebhxb@sdu.edu.cn Supported by Beijing Magtech Co.Ltd